The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction ...
The Food and Drug Administration on March 10 changed the approval for a version of the prescription drug leucovorin to include people with a very rare genetic condition. FDA Commissioner Dr. Marty ...
Sen. Bill Cassidy (R-La.) on Tuesday unveiled his proposal for modernizing the Food and Drug Administration (FDA), calling on the agency to reform some of its practices and embrace innovations in ...
NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER) ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
As the Food and Drug Administration weighs whether to impose new pregnancy warnings on widely prescribed antidepressants, health writer Matthew Perrone ...
Central nervous system disorders represent one of the largest and most complex therapeutic areas globally. The convergence of CNS and oncology research amplifies the significance of Oncotelic’s recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results